Coulter Partners strengthens leadership at IMU Biosciences with placements of Chief Executive Officer and Chief Business Officer

London, November 12, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with IMU Biosciences and is pleased to announce the placements of Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer. Founder and former Chief Executive Officer Dr. Adam Laing will assume the roles of President and Chief Scientific Officer.

IMU Biosciences is a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine.

Dr. Adam Laing, President and CSO of IMU Biosciences, commented: “I am incredibly proud of what the IMU team has achieved to date. We have built a powerful platform that has the potential to revolutionize precision medicine across a range of health conditions. I look forward to continuing to advance our scientific strategy and innovation, and to working closely with John and Jason to realize the full potential of our immune-powered approach.”

He went on to say, “We are incredibly grateful to Coulter Partners for their invaluable assistance in finding two exceptional leaders to join our team. Their expertise in executive search was instrumental in identifying candidates who not only possess the necessary skills and experience but also align perfectly with our company's culture and vision.”

‍Dr. John Baker, incoming Chief Executive Officer at IMU Biosciences, added: “I am excited to join IMU Biosciences at a pivotal moment. The Company's unique approach to immune profiling has huge potential, and I'm looking forward to guiding its continued growth and development. IMU's proprietary technology platforms have the ability to meaningfully impact patient outcomes. Together with Adam, Jason, and the full IMU team, our mission is to advance our pipeline, forge strategic partnerships, and ultimately drive the delivery of life-changing therapies to patients.”

----

Dr. John Baker, PhD, Chief Executive Officer

John Baker joins IMU Biosciences from Abcam, a global life science tools company, where he most recently served as Senior Vice President, Supply Chain and Manufacturing. John has been on the Executive Team at Abcam since 2016, during which time the business delivered exceptional growth, culminating in a successful acquisition for c. $5.7 billion and transition into Danaher Corporation in 2023. During his time at Abcam, John led global teams spanning Business Development, R&D, Product, Marketing, and Supply Chain & Manufacturing. John trained as a veterinarian, undertaking both his undergraduate and clinical training in Cambridge. Following a spell in commercial animal practice, John moved to Oxford for a DPhil in Clinical Medicine, publishing on the molecular biology of the innate immune response. John spent 6 years with Bain and Company in London, where he was a leader in the company’s Global Healthcare Practice. He has previously held Non-Executive Director roles at both BrickBio and Somaserve.

Dr. Jason Brown, PhD, Chief Business Officer

Jason Brown joins IMU Biosciences from Evotec, a leading R&D biotech company, where he served as Senior Vice President of Business Development. Jason brings a wealth of expertise in business development, scientific discovery partnerships, and drug discovery services. Previous roles include founding and leading Ubiquigent, a specialized drug discovery services company in the protein degradation field, where he secured key partnerships and drove scientific innovation. Jason completed a PhD at the University of Cambridge, leading research which resulted in the identification of the molecular target of the blockbuster Pfizer drugs Neurontin™ and Lyrica®. As IMU Biosciences’ first Chief Business Officer, Jason will oversee the Company’s business development and partnering efforts.

[ENDS]

Notes to editors:

About IMU Biosciences

IMU Biosciences has developed proprietary platform technologies that generate and translate vast system-level immune data into actionable insights and tools to drive the development of precision medicines across a variety of diseases. Built on over a decade of research at King’s College London and the Francis Crick Institute, IMU leverages advanced immune profiling with proprietary AI and machine learning analytics to uncover novel clinical immune signatures. IMU continues to establish partnerships with leading Pharma and Biotech companies to advance disease diagnosis, optimize product selection, and improve patient stratification and monitoring—while also building its own pipeline of innovative products.

To learn more please visit www.imubiosciences.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com